Scholarlink

<p>Immune checkpoint therapy (ICT) has revolutionized cancer treatment by restoring cytotoxic T-cell activity, yet primary and acquired resistance remain pervasive. Increasing evidence reveals that such resistance is not dictated solely by tumor-intrinsic factors but arises from the dynamic interplay between malignant and stromal compartments within the tumor microenvironment. Among these, cancer-associated fibroblasts (CAFs)—the dominant stromal population—have emerged as key orchestrators of immune accessibility and therapeutic outcome. Beyond forming structural barriers through extracellular matrix remodeling, CAFs actively shape immune cell recruitment, polarization, and effector functions via diverse cytokines, chemokines, and metabolic pathways. In turn, immune-derived mediators reprogram CAF states, establishing bidirectional feedback circuits that continuously recalibrate stromal and immune homeostasis. These reciprocal networks transform the immune microenvironment into a self-adaptive ecosystem that governs tumor progression and responsiveness to ICT. This review synthesizes recent advances in understanding CAF–immune crosstalk, emphasizing how such interactions drive both primary and acquired resistance to checkpoint blockade. We further highlight emerging therapeutic strategies aimed at reprogramming the CAF–immune axis—rather than eradicating it—to restore durable and systemic antitumor immunity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bidirectional crosstalk between cancer-associated fibroblasts and tumor immunity: shaping the microenvironment and response to immune checkpoint therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月31日

查看全文
  • Shiqing Wang,
  • Di Wang,
  • Yipeng Zhou,
  • Wen Li,
  • Guofu Sun,
  • Lijuan Cao,
  • Chao Feng,
  • Yongjing Chen,
  • Changshun Shao,
  • Qi Gui,
  • Peishan Li,
  • Yufang Shi,
  • Jiankai Fang

摘要

Immune checkpoint therapy (ICT) has revolutionized cancer treatment by restoring cytotoxic T-cell activity, yet primary and acquired resistance remain pervasive. Increasing evidence reveals that such resistance is not dictated solely by tumor-intrinsic factors but arises from the dynamic interplay between malignant and stromal compartments within the tumor microenvironment. Among these, cancer-associated fibroblasts (CAFs)—the dominant stromal population—have emerged as key orchestrators of immune accessibility and therapeutic outcome. Beyond forming structural barriers through extracellular matrix remodeling, CAFs actively shape immune cell recruitment, polarization, and effector functions via diverse cytokines, chemokines, and metabolic pathways. In turn, immune-derived mediators reprogram CAF states, establishing bidirectional feedback circuits that continuously recalibrate stromal and immune homeostasis. These reciprocal networks transform the immune microenvironment into a self-adaptive ecosystem that governs tumor progression and responsiveness to ICT. This review synthesizes recent advances in understanding CAF–immune crosstalk, emphasizing how such interactions drive both primary and acquired resistance to checkpoint blockade. We further highlight emerging therapeutic strategies aimed at reprogramming the CAF–immune axis—rather than eradicating it—to restore durable and systemic antitumor immunity.